Thrombopoietin accumulation in hepatocytes induces a decrease in its serum levels in a sinusoidal obstruction...

Area of Science:

• Hepatology
• Hematology
• Biomarker Discovery

Background:

• Sinusoidal obstruction syndrome (SOS) is a severe hepatic injury linked to drugs like oxaliplatin and bone marrow transplants.
• Extravasated platelet aggregation (EPA) is implicated in SOS development, with platelets interacting with hepatocytes.
• Thrombopoietin (TPO) production involves the JAK2-STAT3 pathway, and altered TPO dynamics are observed in conditions with hepatocyte phagocytosis.

Purpose of the Study:

• To investigate the potential of thrombopoietin (TPO) as a diagnostic biomarker for sinusoidal obstruction syndrome (SOS).

Main Methods:

• A mouse model of SOS was established using monocrotaline (MCT) administration.
• Serum and liver tissue TPO levels were quantified.
• Pathological, immunohistochemical, and reverse transcription-quantitative PCR analyses were performed on liver samples.

Main Results:

• MCT treatment led to a significant decrease in peripheral blood platelet counts.
• Pathological changes were observed in hepatic zone 3 of the SOS model.
• Liver tissue TPO protein levels were elevated, while serum TPO levels were decreased in the SOS model compared to controls.

Conclusions:

• Increased hepatic TPO accumulation in SOS may result from extravasated platelet aggregation (EPA) hindering its release into circulation.
• Reduced serum TPO levels in the context of SOS suggest its potential utility as a biomarker for this condition.